GILD · News · 20261112N

HIV and PrEP Demand Growth

GILEAD SCIENCES, INC. · 2026-11-12 · Importance 38 · Surprise 24

Biktarvy held more than 53% of the U.S. HIV treatment market. Descovy sales were driven primarily by higher demand and average realized price, with PrEP accounting for approximately 80% of Descovy sales. Gilead’s PrEP portfolio includes daily oral Descovy and twice-yearly injectable Yeztugo, which provided incremental contributions to the HIV business. The article also cites strong Biktarvy and Descovy performance but gives no dollar sales or growth rates for these products.

Key facts